Literature DB >> 18803617

Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient.

D Kumar1, S Gourishankar, T Mueller, S Cockfield, J Weinkauf, D Vethanayagam, A Humar.   

Abstract

We report the case of a 54-year-old woman who underwent living-related renal transplantation for end-stage renal disease from IgA nephropathy. She was subsequently diagnosed with antibody-mediated rejection (AMR) and received rituximab, a potent B-cell suppressive agent. After therapy with rituximab, she developed Pneumocystis jirovecii pneumonia (PJP) requiring hospitalization. We discuss the increasing literature for the use of rituximab for AMR and the need for PJP prophylaxis in this setting.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18803617     DOI： 10.1111/j.1399-3062.2008.00345.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN： 1398-2273            Impact factor:   2.228


  8 in total

1.  Infectious complications of immune modulatory agents.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

2.  Metagenomic Next-Generation Sequencing in Diagnosis of a Case of Pneumocystis jirovecii Pneumonia in a Kidney Transplant Recipient and Literature Review.

Authors:  Jie Chen; Ting He; Xiujun Li; Xue Wang; Li Peng; Liang Ma
Journal:  Infect Drug Resist       Date:  2020-08-13       Impact factor: 4.003

3.  Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome.

Authors:  Mai Sato; Shuichi Ito; Masao Ogura; Koichi Kamei; Isao Miyairi; Ippei Miyata; Masataka Higuchi; Kentaro Matsuoka
Journal:  Pediatr Nephrol       Date:  2012-09-05       Impact factor: 3.714

4.  Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.

Authors:  Shuichi Ito; Koichi Kamei; Masao Ogura; Tomohiro Udagawa; Shuichiro Fujinaga; Mari Saito; Mayumi Sako; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2012-10-10       Impact factor: 3.651

Review 5.  Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.

Authors:  Xuqin Jiang; Xiaodong Mei; Di Feng; Xiaojing Wang
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

6.  Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol.

Authors:  Tarig Mohammed Abkur; Mamoun Saeed; Saad Zeinalabdin Ahmed; Ryan McArthur; Maeve Leahy; Hilary O'Leary; Denis O'Keeffe
Journal:  Clin Case Rep       Date:  2015-02-09

7.  A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection.

Authors:  G Hychko; A Mirhosseini; A Parhizgar; N Ghahramani
Journal:  Int J Organ Transplant Med       Date:  2011

Review 8.  Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.

Authors:  Norihiko Goto; Kenta Futamura; Manabu Okada; Takayuki Yamamoto; Makoto Tsujita; Takahisa Hiramitsu; Shunji Narumi; Yoshihiko Watarai
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.